Immatics N.V

NASDAQ:IMTX   3:59:45 PM EDT
11.83
+0.04 (+0.34%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)744.21M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$10.27 Million
Adjusted EPS-$0.40
See more estimates
10-Day MA$11.95
50-Day MA$11.73
200-Day MA$10.97
See more pivots

Immatics N.V Stock, NASDAQ:IMTX

Paul-Ehrlich-Strasse 15, Tuebingen, Baden Wuerttemberg 72076
Germany
Phone: +49.7071.5397.0
Number of Employees: 198

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The firm's clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCERâ„¢). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.